Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines1,4Cost savings from Lenalidomide Sandoz can expand treatment options for patients
Popular supplement may actually be increasing risk of lung and stomach cancer, experts warn dailyrecord.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailyrecord.co.uk Daily Mail and Mail on Sunday newspapers.
Cambridge Cognition Holdings wins £1 million contract for late phase cancer trial directorstalkinterviews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from directorstalkinterviews.com Daily Mail and Mail on Sunday newspapers.
Oncology Social Workers 'Just as Important' as Chemo medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
email article
The role of genetic testing to guide therapy for patients with metastatic breast cancer is expanding. There are now several mutations with approved indications for treatment, and more are being studied.
But for the clinician, knowing which tests to order for a particular patient can be complicated. Furthermore, with research in this area evolving and new information continually published, interpreting assay results and deciding on the best way to apply them can also be difficult. The two main purposes of genetic profiling are to identify targetable mutations with approved therapies and to identify mutations with matched clinical trial options, Zahi Mitri, MD, of Oregon Health & Science University in Portland, told